Parameters PR Group (n=12) SR Group (n=11) P value
Mean Median Mean Median
R (min) 4.8 ± 2.21 5 [3.7, 5.9] 4.9 ± 1.69 5.2 [3.8, 5.4] 1.0
SP (min) 3.8 ± 1.86 4.3 [2.6, 4.8] 3.4 ± 1.88 4.2 [2.8, 4.2] 0.41
D (min) 1.1 ± 0.75 0.9 [0.5, 1.6] 1.4 ± 1.42 0.8 [0.6, 1.2] 0.82
K (mm) 2.0 ± 0.45 2.2 [1.7, 2.2] 1.9 ± 0.84 1.6 [1.3, 2.6] 0.45
MA (mm) 71.9 ± 5.66 72.1 [67.5, 75] 68.7 ± 7.88 70.5 [66.3, 73.9] 0.60
α (°) 61.8 ± 6.30 60.7 [57.8, 67.5] 62.4 ± 11.55 67.4 [55.4, 70.4] 0.55
G (K dynes/cm2) 12.2 ± 5.90 10.9 [9.7, 15.1] 11.9 ± 3.73 13.4 [9.8, 14.4] 0.94
Data are presented as mean ± SD and median [1st Quartile, 3rd Quartile]. Two-tailed P value determined using Mann-Whitney U test. There were no statistically significant differences between the two groups. SD = Standard Deviation; PR = propofol/ remifentanyl; SR = sevoflurane/remifentanyl
Table 2b: Postoperative TEG® Data.
This table provides the preoperative TEG® PM™ measurements for both the PR and SR groups. These measurements include G (overall clot strength), TEG® MA (maximum clot strength), MA Activator (maximum clot strength of activator added), ADP MA (maximum contribution of adenosine diphosphate channel to clot strength), AA MA (maximum contribution of arachidonic acid channel to clot strength), ADP Inhibition (percentage of ADP receptors inhibited), AA Inhibition (percentage of AA receptors inhibited), ADP Aggregation (percentage of ADP aggregation), and AA Aggregation (percentage of AA aggregation).